Correlation Between Ascletis Pharma and Lipella Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Ascletis Pharma and Lipella Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Ascletis Pharma and Lipella Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Ascletis Pharma and Lipella Pharmaceuticals Common, you can compare the effects of market volatilities on Ascletis Pharma and Lipella Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Ascletis Pharma with a short position of Lipella Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Ascletis Pharma and Lipella Pharmaceuticals.

Diversification Opportunities for Ascletis Pharma and Lipella Pharmaceuticals

-0.45
  Correlation Coefficient

Very good diversification

The 3 months correlation between Ascletis and Lipella is -0.45. Overlapping area represents the amount of risk that can be diversified away by holding Ascletis Pharma and Lipella Pharmaceuticals Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Lipella Pharmaceuticals and Ascletis Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Ascletis Pharma are associated (or correlated) with Lipella Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Lipella Pharmaceuticals has no effect on the direction of Ascletis Pharma i.e., Ascletis Pharma and Lipella Pharmaceuticals go up and down completely randomly.

Pair Corralation between Ascletis Pharma and Lipella Pharmaceuticals

Assuming the 90 days horizon Ascletis Pharma is expected to generate 1.62 times more return on investment than Lipella Pharmaceuticals. However, Ascletis Pharma is 1.62 times more volatile than Lipella Pharmaceuticals Common. It trades about 0.17 of its potential returns per unit of risk. Lipella Pharmaceuticals Common is currently generating about 0.03 per unit of risk. If you would invest  24.00  in Ascletis Pharma on December 30, 2024 and sell it today you would earn a total of  96.00  from holding Ascletis Pharma or generate 400.0% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthVery Weak
Accuracy95.38%
ValuesDaily Returns

Ascletis Pharma  vs.  Lipella Pharmaceuticals Common

 Performance 
       Timeline  
Ascletis Pharma 

Risk-Adjusted Performance

Good

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Ascletis Pharma are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile essential indicators, Ascletis Pharma reported solid returns over the last few months and may actually be approaching a breakup point.
Lipella Pharmaceuticals 

Risk-Adjusted Performance

Weak

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Lipella Pharmaceuticals Common are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of very inconsistent basic indicators, Lipella Pharmaceuticals displayed solid returns over the last few months and may actually be approaching a breakup point.

Ascletis Pharma and Lipella Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Ascletis Pharma and Lipella Pharmaceuticals

The main advantage of trading using opposite Ascletis Pharma and Lipella Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Ascletis Pharma position performs unexpectedly, Lipella Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lipella Pharmaceuticals will offset losses from the drop in Lipella Pharmaceuticals' long position.
The idea behind Ascletis Pharma and Lipella Pharmaceuticals Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.

Other Complementary Tools

Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Commodity Directory
Find actively traded commodities issued by global exchanges
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
CEOs Directory
Screen CEOs from public companies around the world
Insider Screener
Find insiders across different sectors to evaluate their impact on performance